Search
for

    Sort by

    Community Join

    450-480 / 1000+ results

      community The New, Improved CB-03-01/Setipiprant Group Buy

       28 upvotes 9 years ago
      The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

      community Opinion about my regiment.....

      in Treatment  6 upvotes 4 years ago
      A user shares their hair loss treatment regimen, which includes oral finasteride, oral and topical minoxidil, RU58841, LLLT cap, microneedling, ketoconazole shampoo, biotin, vitamin D3, NAC supplement, MK677, collagen, and other hair care products. They seek opinions on its effectiveness.

      community Anyone here used spirolactone/cyproterone acetate/bicalutamide?

      in Chat  4 upvotes 7 months ago
      The conversation discusses the use of spironolactone, cyproterone acetate, and bicalutamide for hair loss, with concerns about side effects like gynecomastia and depression. Topical spironolactone is considered safe for men and effective when combined with regular treatments.

      community Status update on upcoming treatments

      in Technology  43 upvotes 4 months ago
      Current treatments for hair loss include finasteride, minoxidil, and derma rolling. New treatments like Breezula, PP405, and others are not expected until at least 2027 or later.

      community Lets do this!!! My current Stack

      in Treatment  4 upvotes 1 year ago
      The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.

      community What are your thoughts on this solution?

      in Treatment  15 upvotes 1 year ago
      The conversation discusses hair loss treatments, focusing on the use of Minoxidil, finasteride, and triamcinolone. Concerns are raised about high concentrations of Minoxidil and the long-term use of corticosteroids.
      The story of RU58841/ PSK3841

      community The story of RU58841/ PSK3841

      in Research  622 upvotes 1 year ago
      RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

      community How long still for CB-03-01? (breezula)

      in Question  7 upvotes 6 years ago
      The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
      Last Attempt at Fighting The Curse

      community Last Attempt at Fighting The Curse

      in General  210 upvotes 4 months ago
      The user is using minoxidil, finasteride, dutasteride, and clobetasol, along with needling, to combat hair loss. They are considering stopping treatment if no improvement is seen.

      community Topical solution recommendation

      in Treatment  2 upvotes 8 months ago
      The user is using finasteride 1mg every other day and seeks a topical solution excluding minoxidil. They are considering various combinations of ingredients like finasteride, dutasteride, and tofacitinib, with options for nourishing oils and other additives.

      community Treatments to maintain alternative to finasteride/dutasteride

      in Treatment  6 upvotes 4 years ago
      A 29-year-old male experiencing hair loss due to TRT is using minoxidil and dermarolling but is hesitant to use finasteride or dutasteride due to potential side effects. He is considering low level laser therapy (LLLT), PRP, ketoconazole shampoo, and oral minoxidil as additional treatments. A reply suggests that without a DHT blocker like finasteride or dutasteride, other treatments may not be effective long-term.

      community 2 years of Androgen inhibition.

      in Progress Pictures  144 upvotes 7 months ago
      A 23-year-old has been using finasteride, dutasteride, and spironolactone to combat hair loss and hormonal acne, with mixed results and concerns about side effects. The user is experimenting with spironolactone despite its potential risks, hoping for skin and body hair improvements.

      community Ruxolitinib - Start of a case study

      in Research/Science  10 upvotes 1 year ago
      The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

      community HMI-115 question about potential earliest access

      in Research/Science  10 upvotes 3 years ago
      Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

      community How’s RCH-01 doing?

      in Treatment  6 upvotes 6 years ago
      RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

      community The real stack, the only things you really need.

      in Treatment  1 upvotes 1 year ago
      The conversation discusses a hair loss prevention regimen using a custom topical treatment with Dutasteride, Minoxidil, Latanoprost, Cetirizine, Tretinoin, Vitamin D3, and caffeine, along with supplements like iron, selenium, vitamin D, and vitamin B. The user advises against expensive treatments like LLLT caps and unnecessary natural supplements.

      community Are these new hair loss treatments ever gonna release?

      in Technology  44 upvotes 4 weeks ago
      Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.